All In Biotech

Drug Trial Radar · NCT01736592

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

27

Actual

Start

Dec 14, 2012

Primary completion

Aug 29, 2033

Study completion Aug 29, 2033

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity

Conditions

  • Stargardt's Disease

Interventions

  • Long term follow up in all patients who received SAR422459 in previous study TDU13583Drug

    Blood draw for the laboratory assessment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Adverse EventsTime frame: 15 years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Oregon Health and Science University Site Number : 840001

    Portland, Oregon

  • Investigational Site Number : 250001

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.